Product Reports Resources Pricing Login Book a demo

AbCellera Biologics

Biotech & Life Sciences · Vancouver, Canada · Founded 2012 · IPO 2020

Innovator in antibody discovery for therapeutics, and immune profiling for vaccine research

Valuation $1.38B
Revenue $32M

Talent graph

AbCellera Biologics's talent

Book a demo to see the people
Employees mapped 590 incl. 22 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 13 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

8 investors on AbCellera Biologics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 7 investors entered at this stage
Northview LifeSciences
Viking Global Investors
The University of British Columbia
OrbiMed
Peter Thiel
Eli Lilly
Presight Capital

Global footprint

Where AbCellera Biologics has talent and traffic

Workforce by country
8 countries with
team presence
🇨🇦 Canada82%
🇦🇺 Australia9.8%
🇺🇸 United States5.7%
🇮🇪 Ireland1.3%
🇮🇳 India0.6%
Top 5 of 8 shown
Web traffic by country
29K monthly visits
across markets
🇨🇦 Canada37.2%
🇺🇸 United States26.2%
🏳️ Korea11.4%
🏳️ Republic of8.6%
🇦🇺 Australia6.6%
Top 5 markets shown

Patent intelligence

$83M patent portfolio · 56 active families

Estimated portfolio value
$83M
6.0% of market cap · 2.7× smaller than top peer Ganymed Pharmaceuticals ($226M)
56 active patent families
Where AbCellera Biologics innovates Antiendomysial antibodiesDiseaseMolecular biologyAnti antibodyAntibody

Where AbCellera Biologics concentrates vs peers

Each axis is a top-10 topic across AbCellera Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

AbCellera Biologics's 5 investments and acquisitions.

Every disclosed deal where AbCellera Biologics appeared as a backer or acquirer, 2020–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

5 deals across AbCellera Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where AbCellera Biologics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        AbCellera Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        5 of 5 deals

        Market sentiment

        What the market is saying about AbCellera Biologics

        An AI-synthesized read of the highest-engagement posts about AbCellera Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See AbCellera Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.